Ea­ger to re­deem its Covid-19 vac­cine, As­traZeneca touts 82.4% ef­fi­ca­cy for 12-week dos­ing sched­ule — but will the FDA buy it?

As­traZeneca and Ox­ford say they now have clin­i­cal ev­i­dence that dos­ing their ade­n­ovirus-based Covid-19 vac­cine 12 weeks apart — a reg­i­men ap­proved by the UK, per­plex­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.